Home-monitoring device helps to detect CNV earlier
Early detection leads to better preservation of vision.
Home monitoring with a preferential hyperacuity perimetry device may allow for early detection of choroidal neovascularization-related changes in patients with early age-related macular degeneration.
The earlier neovascular AMD is treated, the better final visual acuity outcomes will be. However, early treatment requires early detection in order to be efficient.
The ForeseeHome AMD monitoring program (Notal Vision) is the first FDA-cleared system for home-based monitoring of at-risk patients in order to improve upon current standards of early detection.
“Early detection means better preservation of vision, better outcomes of therapy,” Anat Loewenstein, MD, OSN Europe Edition Board Member, said in a presentation at the FLOREtina meeting in Florence, Italy.
Importance of early detection
Subgroup analysis of the CATT trial, the U.K. Neovascular Age-Related Macular Degeneration EMR Database multicenter study and other studies with up to 5 years of follow-up showed that small lesion size and better visual acuity at baseline predict a better visual acuity outcome.
Current standard of care in detecting choroidal neovascularization (CNV) consists of prescheduled physician visits or using the Amsler grid. Loewenstein considers these methods ineffective in early detection.
“When you look at the visual acuity of patients who enter studies in the last 10 years, you can see that there is only a small percentage of them that come with a good function of visual acuity. And this is just in the studies, let alone in real life,” she said. “So, most CNV patients, when they show up, do not start or end with a functional visual acuity outcome.”………
Read more: http://www.healio.com/ophthalmology/retina-vitreous/news/print/ocular-surgery-news-europe-edition/%7Be746037e-74cc-4b1c-95d7-31734504fd96%7D/home-monitoring-device-helps-to-detect-cnv-earlier